12 Best Emerging Technology Stocks to Invest In

8. Inhibrx Biosciences Inc. (NASDAQ:INBX)

Number of Hedge Fund Holders: 18

Inhibrx Biosciences Inc. (NASDAQ:INBX) is one of the best emerging technology stocks to invest in. On December 16, Inhibrx Biosciences provided a comprehensive progress update regarding its primary oncology programs. The company is currently advancing two lead therapeutic candidates: INBRX-106, which is a hexavalent sdAb-based OX40 agonist, and ozekibart (INBRX-109), which is a tetravalent death receptor 5 (DR5) agonist. These candidates use precise protein engineering to optimize immune system activation and tumor-targeted cell death.

The INBRX-106 program is centered on a Phase 2/3 clinical trial evaluating the drug in combination with Keytruda (pembrolizumab) as a first-line treatment for locally advanced unresectable or metastatic head and neck squamous cell carcinoma/HNSCC. As of December, Inhibrx recruited 46 out of the 60 patients required for the randomized Phase 2 portion of this study. The trial enrolls patients who have not received prior systemic therapy and exhibit a tumor PD-L1 CPS expression of 20 or greater. Enrollment for this Phase 2 portion is expected to be completed in Q1 2026.

Simultaneously, the company progressed its investigation of INBRX-106 in combination with Keytruda for patients with non-small cell lung cancer/NSCLC who are refractory to or have relapsed after checkpoint inhibitor therapy. Enrollment for this 34-patient Phase 1/2 trial cohort was finalized in November. While the current datasets for both the HNSCC and NSCLC trials are not yet mature enough to support conclusions, Inhibrx expects that the data will be sufficiently mature by H2 2026 to determine if the combination therapy provides a sustained clinical benefit over the current standard of care.

Regarding the ozekibart (INBRX-109) program, Inhibrx completed enrollment in late October for an expansion cohort of 44 patients in a Phase 1/2 trial. The study evaluates ozekibart combined with FOLFIRI in patients with heavily pretreated advanced or metastatic colorectal cancer, specifically those in the third and fourth lines of treatment. Previous reports indicated the combination was well-tolerated with high disease control rates. The company expects progression-free survival data from this cohort to reach maturity in Q2 2026.

Inhibrx Biosciences Inc. (NASDAQ:INBX) is a clinical-stage biopharmaceutical company that develops biologic therapeutics for people with life-threatening conditions.